Immunovant, Inc. balance sheet IMVT

Annual Quarterly

As of Jun 30, 2026, Immunovant, Inc. had total assets of $852.5 million and total liabilities of $117.1 million. Total assets were up 28.9% from a year earlier. Stockholders' equity was $735.4 million. Cash and investments were $797.8 million. The current ratio, current assets divided by current liabilities, was 7.27.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line	Q1 FY2027 Jun 30, 2026	Q4 FY2026 Mar 31, 2026	Q3 FY2026 Dec 31, 2025	Q2 FY2026 Sep 30, 2025	Q1 FY2026 Jun 30, 2025	Q4 FY2025 Mar 31, 2025	Q3 FY2025 Dec 31, 2024	Q2 FY2025 Sep 30, 2024
Assets
Cash	798 +33.2%	902 +26.4%	995 +165.4%	522 +10.3%	599 +6.9%	714 +12.4%	375 -45.8%	473 +75.2%
Cash and investments	798 +33.2%	902 +26.4%	995 +165.4%	522 +10.3%	599 +6.9%	714 +12.4%	375 -45.8%	473 +75.2%
Receivables	1 -64.0%	1 -45.6%	2 -26.1%	2 +5.0%	2 -19.9%	2 -61.0%	2 +116.1%	2 +32.0%
Total current assets	851 +30.6%	949 +23.6%	1,043 +152.8%	574 +13.0%	652 +10.6%	768 +15.3%	413 -42.0%	507 +74.2%
Property and equipment, net	0 -52.4%	0 -47.5%	1 -29.4%	1 -5.8%	1 +30.4%	1 +82.7%	1 +100.0%	1 +120.7%
Total assets	852 +28.9%	957 +23.3%	1,052 +150.0%	583 +13.0%	661 +12.2%	776 +16.5%	421 -40.8%	516 +76.6%
Liabilities and equity
Accounts payable	10 +29.3%	8 -57.3%	9 -56.5%	7 -66.6%	8 -28.9%	18 +146.8%	20 +406.8%	21 +176.0%
Total current liabilities	117 +121.4%	104 +51.8%	66 -3.0%	63 -5.1%	53 +17.5%	69 +41.5%	68 +112.8%	67 +65.6%
Total liabilities	117 +121.4%	104 +51.8%	66 -3.0%	63 -5.1%	53 +17.5%	69 +41.5%	68 +112.8%	67 +65.6%
Stockholders' equity	735 +20.8%	853 +20.5%	986 +179.7%	520 +15.7%	609 +11.7%	707 +14.5%	353 -48.1%	449 +78.3%
Debt
Lease liabilities	—	0 -26.5%	—	—	—	0 -29.0%	0 -92.5%	0 -92.3%
Total debt	—	0 -26.5%	—	—	—	0 -29.0%	0 -92.5%	0 -92.3%
Net cash	—	902 +26.4%	—	—	—	714 +12.4%	375 -45.8%	473 +75.6%
Ratios
Current ratio	7.27x	9.09x	15.74x	9.07x	12.32x	11.16x	6.04x	7.61x
Debt to equity	—	0.00x	—	—	—	0.00x	0.00x	0.00x
Return on equity	-73.19%	-59.30%	-47.07%	-89.41%	-73.50%	-58.50%	-108.53%	-71.93%
Return on assets	-63.13%	-52.83%	-44.11%	-79.71%	-67.63%	-53.31%	-90.92%	-62.63%
Book value per share	3.57	4.18	4.85	2.98	3.56	4.16	2.40	3.06

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: IMVT (Nasdaq)
Fiscal year ends: March 31
Incorporated in: DE
Headquarters: Durham, NC
SEC filer status: Large accelerated filer
SEC CIK: 1764013
Former names: Health Sciences Acquisitions Corp (until Dec 20, 2019)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.